Estradiol topical cream is a compounded, prescription preparation of estradiol in a cream base that you rub into the skin. Estradiol is the main estrogen your ovaries make before menopause, and levels fall as menopause approaches. Applied to the skin, estradiol is absorbed through the skin into the bloodstream, so it works throughout the body rather than only where you put it.
It is prepared by a licensed pharmacy at the strength and volume your prescriber orders rather than mass-produced. FDA-approved transdermal estradiol products are widely available in the United States, including EstroGel 0.06%, Elestrin, Divigel, the Evamist spray, and estradiol patches. Because those approved options are broad, a compounded systemic estradiol cream is the hardest of the hormone preparations to justify. Only your prescriber can decide whether it is right for you.
How does it work?
Estradiol is the main estrogen the ovaries produce before menopause. When you rub the cream into your skin, estradiol passes through the skin and into the bloodstream, where it acts on tissues throughout the body — which is why it can help with symptoms like hot flashes that are not limited to one area. Because it is absorbed through the skin, it does not pass through the liver first the way a swallowed tablet does. In observational and mechanistic data, that difference has been associated with a lower risk of blood clots and stroke than with estrogen taken by mouth. That comparison is between transdermal and oral estrogen in general; it is not a statement that a compounded cream performs better than an FDA-approved transdermal product.
What is it used for?
Prescribers use systemic estradiol for menopausal symptoms — hot flashes, night sweats, and the sleep disruption that comes with them — and for protection against bone loss. The Menopause Society's 2022 Hormone Therapy Position Statement supports what is often called the timing hypothesis: for women with symptoms who are under 60 or within 10 years of the onset of menopause, the benefits of hormone therapy generally outweigh the risks, and the balance becomes less favorable when therapy is started later (The Menopause Society).
Professional guidance is specific about compounded versions. The 2020 report from the National Academies of Sciences, Engineering, and Medicine recommends restricting compounded bioidentical hormone therapy to two circumstances: an allergy to an ingredient in an FDA-approved product, or a need for a dosage form that is not commercially available (NASEM, 2020). ACOG Clinical Consensus No. 6 (November 2023) states that compounded formulations should not be routinely prescribed when FDA-approved options exist, that salivary or serum hormone testing is not recommended for dosing, and that patients should be counseled that these products lack FDA approval. Bayview Pharmacy does not provide consultations or determine appropriateness, and a valid prescription is required.
How do the strengths compare?
Estradiol cream is compounded across a range of concentrations. The concentration is only half the picture: the amount of estradiol you actually absorb depends on the concentration, the volume you apply, where you apply it, and your own skin. The table below describes the common concentrations for education only.
| Strength | Notes |
|---|---|
| Estradiol 0.5 mg/gm | A lower concentration, often ordered when starting or stepping down |
| Estradiol 1 mg/gm | A commonly ordered concentration |
| Estradiol 1.5 mg/gm | An intermediate concentration |
| Estradiol 2 mg/gm | Delivers more estradiol in the same volume of cream |
| Estradiol up to 4 mg/gm | Ordered when the prescriber wants more estradiol in a small volume |
| Prefilled syringes (for example, 1 mg per 0.1 mL) | Single measured doses dispensed as a set of syringes |
Strengths are described for education only and are not a statement that any concentration is better for a particular person. Dose delivery from compounded creams is imprecise: published comparisons of compounded transdermal estradiol against FDA-approved products have found meaningfully different or variable estrogen exposure. Your prescriber selects the strength, volume, and schedule.
How is it used?
Use it exactly as your prescriber directs. A common regimen is a measured pump dose, or 0.5 to 1 mL from a prefilled syringe, applied once daily to the inner forearm, inner thigh, or abdomen, rotating sites from day to day. Rub it in and let the skin dry completely before dressing. Wash your hands with soap and water right after applying, and do not apply the cream to your breasts. Prescribers generally aim for the lowest effective dose and retitrate based on your symptoms rather than on lab numbers — ACOG specifically does not recommend salivary or serum hormone testing to guide dosing.
Because estradiol can transfer from skin to skin, keep the treated area covered or fully dry before close contact with children, partners, or pets. If your preparation uses an alcohol-containing base, treat it as flammable until the skin is dry and keep it away from open flame. Do not change the dose or stop on your own; talk with your prescriber first. A Bayview pharmacist is available if you have questions about your prescription.
Side effects & safety
The more common effects are breast tenderness, bloating, headache, nausea, mood changes, breakthrough or unexpected vaginal bleeding, and irritation where you apply the cream. Serious risks associated with estrogen therapy include blood clots in the legs or lungs (DVT and pulmonary embolism), stroke, gallbladder disease, endometrial hyperplasia or endometrial cancer when estrogen is used without adequate progestogen in someone with a uterus, and a breast cancer signal with longer-duration combined estrogen-progestogen therapy. Tell your prescriber about any unexpected vaginal bleeding, leg swelling or pain, chest pain, shortness of breath, or sudden severe headache or vision change.
About boxed warnings. On November 10, 2025, HHS and the FDA announced the removal of boxed-warning language about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products, and on February 12, 2026 the FDA approved those labeling changes for a first set of six products, with roughly 29 more still pending (FDA, February 2026). The boxed warning about endometrial cancer was not removed for systemic estrogen-alone products. Labeling is in the middle of this transition, and compounded preparations carry no FDA-approved labeling at all. None of this means estrogen therapy is without risk.
Who should not use it?
Based on the labeling for FDA-approved estradiol products, estrogen should not be used if you have undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; a known or suspected estrogen-dependent cancer; active or prior deep vein thrombosis or pulmonary embolism; active or prior arterial thromboembolic disease such as stroke or heart attack; liver impairment; a known blood-clotting disorder (thrombophilia); a known hypersensitivity to estradiol or to any ingredient in the preparation; or if you are or may be pregnant. Tell your prescriber about your full health history, allergies, and every medication and supplement you take so they can decide whether this preparation is appropriate for you.
How should it be stored?
Store at controlled room temperature, about 20 to 25 °C (68 to 77 °F), with the container tightly closed and away from heat and light. Do not freeze it. Keep it out of the reach of children and pets, and do not share it with anyone. Follow the beyond-use date on your label and do not use the preparation after that date. Dispose of unused medication as your pharmacist directs.
Why is this compounded?
Compounding lets a licensed pharmacy prepare estradiol at a strength, volume, or base that is not sold commercially — for example a specific concentration in a fragrance-free base, or single measured doses in prefilled syringes. It is worth being direct about the trade-off: because FDA-approved transdermal estradiol products are broadly available, a compounded systemic estradiol cream is the hardest of the hormone preparations to justify, and both NASEM and ACOG advise reserving compounded hormone therapy for a documented ingredient allergy or a dosage form that is not commercially available. As a 503A compounding pharmacy, Bayview Pharmacy prepares each order in small batches from quality ingredients. Compounded preparations are not FDA-approved, they are not reviewed by the FDA for safety, effectiveness, or manufacturing quality, and a valid prescription is required.
Clinical details for prescribers
Regulatory status. Estradiol is not a controlled substance. Multiple FDA-approved transdermal estradiol products exist (EstroGel 0.06%, Elestrin, Divigel, Evamist spray, transdermal patches), so a compounded systemic cream should be supported by a documented rationale — ingredient allergy or a dose/dosage form not commercially available (NASEM 2020; ACOG Clinical Consensus No. 6, Nov 2023). The FDA's March 2024 proposed rule on drug products presenting demonstrable difficulties for compounding covered only modified-release oral solids, liposomal products, and hot-melt-extrusion products; estradiol was not included, and the rule is not final. Compounded preparations are not FDA-approved.
Formulation & SIG. Estradiol in a cream base (commonly VersaBase), typically 0.5, 1, 1.5, 2, and up to 4 mg/gm; jars of 30, 45, 60, 90, or 180 g, or sets of prefilled 0.1 mL syringes (e.g., 1 mg/0.1 mL × 9). Typical SIG (descriptive only): apply one measured pump dose, or 0.5–1 mL, to the inner forearm, inner thigh, or abdomen once daily, rotating sites; rub in and allow to dry. Titrate to the lowest effective dose by symptom response.
Clinical points:
- Transdermal delivery bypasses first-pass hepatic metabolism; observational and mechanistic data associate this with lower VTE and stroke risk than oral estrogen
- The Menopause Society 2022 position statement supports the timing hypothesis — favorable benefit–risk for symptomatic women <60 years or within 10 years of menopause onset
- Intact uterus requires adequate concurrent progestogen for endometrial protection; endometrial protection adequacy with compounded progesterone is a known evidence gap
- Dose delivery from compounded creams is imprecise; published comparisons against approved products found meaningfully different or variable estrogen exposure
- Salivary and serum hormone testing is not recommended for dosing (ACOG Clinical Consensus No. 6)
- Boxed-warning labeling is mid-transition: CV disease, breast cancer, and probable dementia language is being removed (HHS/FDA Nov 2025; first six product labels approved Feb 2026, ~29 pending), while the endometrial cancer boxed warning remains for systemic estrogen-alone products. Compounded preparations carry no FDA-approved labeling.
- Counsel on secondary transfer to children, partners, and pets; avoid breast application; alcohol-containing bases are flammable until dry
Ordering: send a prescription to Bayview Pharmacy, 3844 Post Rd, Warwick, RI 02886 (NCPDP 4106882, fax 401-284-4506). Background: FDA on the NASEM cBHT study; EstroGel 0.06% prescribing information.
This is a prescription compounded medication and is not FDA-approved. This information is educational and is not medical advice. Bayview Pharmacy does not provide consultations or determine appropriateness; your prescriber decides whether this preparation is appropriate and sets the strength and dose.
